Want to see KR:007460 full AI Analyst Report?
Top Page
Aprogen, Inc
(007460)
Select Model
Select Model
Rating:41Neutral
Price Target:
₩1,828.00
Action:N/A
Date:10/28/26
The score is primarily constrained by weak financial performance: persistent deep losses, significant ongoing cash burn, and a notable increase in leverage. Technicals add further pressure with the stock trading below all major moving averages and negative MACD momentum. Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Positive Factors
Revenue Growth
Revenue growth indicates that Aprogen is expanding its top line and gaining commercial or development traction in biologics. If sustained, this provides a broader base for operating leverage and could support future earnings improvement, although current profitability remains weak.
Negative Factors
Persistent Losses
Deep and persistent losses show that Aprogen is not yet converting its biologics revenue base into sustainable earnings. Continued negative operating performance can constrain reinvestment, increase dependence on external funding, and delay the point at which growth becomes self-financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth indicates that Aprogen is expanding its top line and gaining commercial or development traction in biologics. If sustained, this provides a broader base for operating leverage and could support future earnings improvement, although current profitability remains weak.
Read all positive factors
Aprogen, Inc (007460) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩9.15B
Dividend YieldN/A
Average Volume (3M)126.83K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth9.08%
EPS Growth-32.52%
CountryKR
Employees311
SectorGeneral
Sector StrengthN/A
IndustryConglomerates
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,650,015
10 Day Avg. Volume101,000
30 Day Avg. Volume126,828
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)1.46
Price to Sales (P/S)1.95
P/FCF Ratio-5.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aprogen, Inc Business Overview & Revenue Model
Company Description
Founded in 1971 and headquartered in Seongnam-si, South Korea, Aprogen Medicines Inc. (formerly Aprogen KIC Inc. until its name change in April 2021) specializes in the design, manufacture, and maintenance of plant facilities. Their services cater...
Aprogen, Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
29
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 138.90B | 117.97B | 150.11B | 150.58B | 78.35B | 141.25B |
| Gross Profit | 28.17B | 33.24B | 34.90B | 35.81B | 6.15B | 31.25B |
| EBITDA | -120.85B | -113.95B | -73.38B | -65.54B | -76.10B | -72.32B |
| Net Income | -82.81B | -69.48B | -58.08B | -55.62B | -116.08B | -12.50B |
Balance Sheet | ||||||
| Total Assets | 674.45B | 718.99B | 609.97B | 594.43B | 599.85B | 824.11B |
| Cash, Cash Equivalents and Short-Term Investments | 43.16B | 50.15B | 43.66B | 40.68B | 47.46B | 159.81B |
| Total Debt | 181.45B | 187.86B | 113.70B | 124.42B | 90.20B | 78.98B |
| Total Liabilities | 259.93B | 256.56B | 169.88B | 176.74B | 138.85B | 119.75B |
| Stockholders Equity | 60.54B | 156.71B | 158.63B | 147.80B | 215.09B | 335.95B |
Cash Flow | ||||||
| Free Cash Flow | -86.73B | -42.75B | -68.14B | -113.04B | -138.31B | -10.72B |
| Operating Cash Flow | -63.90B | -33.76B | -44.99B | -58.16B | -113.49B | -8.61B |
| Investing Cash Flow | -11.90B | -62.74B | -40.50B | -43.45B | 70.17B | -32.46B |
| Financing Cash Flow | -22.52B | 102.98B | 86.62B | 94.30B | 70.80B | 6.61B |
Aprogen, Inc Technical Analysis
Negative
―
Price Trends
2084.20
Negative
2312.20
Negative
4259.10
Negative
Market Momentum
-53.29
Positive
38.93
Neutral
36.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:007460, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1979.65, equal to the 50-day MA of 2084.20, and equal to the 200-day MA of 4259.10, indicating a bearish trend. The MACD of -53.29 indicates Positive momentum. The RSI at 38.93 is Neutral, neither overbought nor oversold. The STOCH value of 36.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:007460.
Aprogen, Inc Peers Comparison
UnderperformOutperform
Sector (55)
KR:007460
Aprogen, Inc
1,870.00
-6,830.00
-78.51%
KR:068330
ilShinbiobase Co., Ltd.
1,009.00
-443.73
-30.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.